Lido Advisors LLC Buys 2,671 Shares of West Pharmaceutical Services, Inc. $WST

Lido Advisors LLC lifted its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 187.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 4,094 shares of the medical instruments supplier’s stock after purchasing an additional 2,671 shares during the period. Lido Advisors LLC’s holdings in West Pharmaceutical Services were worth $1,026,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Brendel Financial Advisors LLC purchased a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $3,742,000. Birch Hill Investment Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 11.5% during the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock worth $41,862,000 after purchasing an additional 15,678 shares during the period. Annex Advisory Services LLC grew its stake in shares of West Pharmaceutical Services by 8.7% in the fourth quarter. Annex Advisory Services LLC now owns 122,958 shares of the medical instruments supplier’s stock worth $33,831,000 after purchasing an additional 9,800 shares during the last quarter. Hsbc Holdings PLC increased its holdings in West Pharmaceutical Services by 23.3% during the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after purchasing an additional 27,745 shares during the period. Finally, Conestoga Capital Advisors LLC increased its holdings in West Pharmaceutical Services by 6.7% during the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after purchasing an additional 8,179 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

WST stock opened at $331.52 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The firm has a 50-day moving average of $337.57 and a 200 day moving average of $287.85. The company has a market cap of $23.33 billion, a P/E ratio of 42.45, a PEG ratio of 2.56 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same period in the previous year, the firm posted $1.84 EPS. The business’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be given a dividend of $0.22 per share. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is currently 11.27%.

Analyst Ratings Changes

A number of research analysts have commented on WST shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday. BNP Paribas Exane started coverage on West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. KeyCorp upped their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Wolfe Research started coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target for the company. Finally, Evercore reaffirmed an “outperform” rating and issued a $425.00 price target on shares of West Pharmaceutical Services in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $364.42.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.